Wechselwirkungen · Raxone
Raxone 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 3–4
HOS-132020 · Präparat HOS-097176
3 were administered together. After repeated administration Cmax and AUC of midazolam were increased by 28% and 34%, respectively, when midazolam was administered in combination with 300 mg idebenone t.i.d. Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving idebenone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) ergot alkaloids (HOS-108807) tacrolimus (HOS-085202) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-20T15:23:00Z · SHA-256 27500298ab701035c3441bc2480ad7b892adfeab7238f85574eb8e5a529c19e1 · Passage 9a05a3b0d707914465607ca103e0f407d599a8f7b1a14726958377862cd7376e · Zeichen 660–1181 im Abschnitt